BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
BioCryst Pharmaceuticals Inc (BCRX) Financials: Revenue, Profit and Cash Flow
BioCryst Pharmaceuticals reported revenue of $874.84M for the fiscal year ended Dec 31, 2025, up 94.1% from the year before. That year, net income was $263.86M with a net margin of 30.2%, operating cash flow was $347.37M and free cash flow was $344.90M. The quarter ended Sep 30, 2026 had revenue of $180.29M and net income of $37.92M.
Revenue and Margins
The operating margin was 39.0% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $26.35M, a compound annual rate of 47.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $874.84M | +94.1% | 97.8% | 39.0% | 30.2% |
| Dec 2024 | $450.71M | +36.0% | 97.3% | -0.6% | -19.7% |
| Dec 2023 | $331.41M | +22.4% | 98.6% | -31.3% | -68.4% |
| Dec 2022 | $270.83M | +72.3% | 97.6% | -54.8% | -91.2% |
| Dec 2021 | $157.17M | +782.4% | 95.4% | -113.1% | -117.1% |
| Dec 2020 | $17.81M | -63.5% | 91.3% | -981.1% | -1026.4% |
| Dec 2019 | $48.84M | +136.5% | 92.4% | -203.7% | -223.0% |
| Dec 2018 | $20.65M | -18.0% | 100.0% | -456.2% | -490.3% |
| Dec 2017 | $25.19M | -4.4% | 95.5% | -227.9% | -261.2% |
| Dec 2016 | $26.35M | N/A | 91.3% | -184.4% | -209.3% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 194.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M | $48.84M | $20.65M | $25.19M | $26.35M |
| Cost of revenue | $19.07M | $12.27M | $4.48M | $6.41M | $7.23M | $1.55M | $3.73M | $0 | $1.14M | $2.30M |
| Gross profit | $855.76M | $438.44M | $326.93M | $264.42M | $149.94M | $16.26M | $45.11M | $20.65M | $24.04M | $24.06M |
| Research and development | $166.13M | $174.64M | $216.57M | $253.30M | $208.81M | $122.96M | $107.07M | $84.89M | $66.96M | $61.01M |
| Operating income | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M | -$174.76M | -$99.45M | -$94.22M | -$57.41M | -$48.61M |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M | -$182.81M | -$108.90M | -$101.25M | -$65.78M | -$55.14M |
| EBITDA | $351.52M | -$1.13M | -$96.87M | -$49.86M | -$122.74M | -$170.56M | -$97.34M | -$92.56M | -$55.67M | -$47.04M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $180.29M | $218.25M | $156.41M | $406.56M | $159.40M | $163.35M | $145.53M | $131.53M | $117.08M | $109.33M | $92.76M | $93.40M |
| Gross profit | $178.72M | $214.41M | $151.04M | $397.03M | $157.21M | $160.56M | $140.97M | $125.44M | $113.87M | $107.63M | $91.50M | $91.84M |
| Operating income | $53.33M | $98.47M | -$701.60M | $260.38M | $29.59M | $29.79M | $21.23M | -$4.51M | $7.69M | $8.76M | -$14.49M | -$42.67M |
| Net income | $37.92M | $78.39M | -$721.81M | $245.84M | $12.90M | $5.08M | $32.00K | -$26.80M | -$14.03M | -$12.67M | -$35.38M | -$61.73M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $1.63M by $88.11M. Shareholder equity was negative, at -$119.15M, as total liabilities of $633.31M exceeded total assets of $514.16M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $514.16M | $490.42M | $516.96M | $550.00M | $588.15M | $334.71M | $175.28M | $146.84M | $178.26M | $89.85M |
| Current assets | $404.35M | $421.97M | $495.97M | $516.50M | $566.14M | $323.80M | $164.34M | $114.35M | $125.39M | $66.99M |
| Cash and equivalents | $89.74M | $104.71M | $110.64M | $304.77M | $504.39M | $272.13M | $114.17M | $26.73M | $50.28M | $22.10M |
| Total liabilities | $633.31M | $966.35M | $972.49M | $844.60M | $695.14M | $353.98M | $137.03M | $97.61M | $94.49M | $88.27M |
| Short-term debt | $1.63M | $35.45M | $2.65M | $2.37M | $1.82M | $30.00M | $38.58M | $33.70M | $35.22M | $28.24M |
| Long-term debt | $0 | $314.87M | $303.23M | $231.62M | $136.08M | $119.73M | $41.29M | $25.37M | $16.75M | $22.78M |
| Shareholder equity | -$119.15M | -$475.93M | -$455.53M | -$294.60M | -$106.99M | -$19.26M | $38.25M | $49.23M | $83.77M | $1.58M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $591.07M | $557.85M | $465.05M | $514.16M | $446.42M | $457.19M | $480.05M | $490.42M | $491.25M | $472.42M | $467.89M | $516.96M |
| Total liabilities | $988.45M | $1.01B | $1.02B | $633.31M | $834.31M | $878.78M | $931.97M | $966.35M | $959.82M | $948.02M | $944.06M | $972.49M |
| Cash and equivalents | $96.97M | $154.97M | $171.59M | $89.74M | $84.08M | $88.03M | $105.19M | $104.92M | $96.84M | $78.41M | $84.33M | $110.64M |
| Shareholder equity | -$397.38M | -$454.29M | -$553.84M | -$119.15M | -$387.89M | -$421.59M | -$451.93M | -$475.93M | -$468.56M | -$475.61M | -$476.17M | -$455.53M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.3% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $347.37M | -$52.02M | -$95.14M | -$161.85M | -$142.16M | -$135.11M | -$89.58M | -$92.56M | -$41.14M | -$53.44M |
| Capital expenditures | $2.47M | $1.12M | $2.17M | $1.35M | $2.38M | $514.00K | $343.00K | $366.00K | $328.00K | $5.28M |
| Free cash flow | $344.90M | -$53.14M | -$97.31M | -$163.20M | -$144.54M | -$135.62M | -$89.93M | -$92.93M | -$41.47M | -$58.72M |
| Investing cash flow | -$13.69M | $52.59M | -$131.50M | -$128.24M | $15.80M | -$6.86M | $77.93M | $4.77M | -$64.64M | $23.27M |
| Financing cash flow | -$349.93M | -$5.76M | $32.48M | $88.03M | $359.67M | $300.59M | $99.10M | $62.50M | $135.70M | $23.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.98M | $104.34M | -$61.79M | $291.96M | $41.62M | $41.30M | -$27.52M | -$5.21M | $8.24M | -$1.37M | -$53.68M | -$8.92M |
| Capital expenditures | $233.00K | $209.00K | $403.00K | $802.00K | $1.34M | $179.00K | $143.00K | $675.00K | $59.00K | $155.00K | $235.00K | $554.00K |
| Free cash flow | $32.75M | $104.13M | -$62.19M | $291.16M | $40.28M | $41.12M | -$27.66M | -$5.89M | $8.19M | -$1.52M | -$53.92M | -$9.47M |
Frequently Asked Questions About BCRX
What is BioCryst Pharmaceuticals' annual revenue?
BioCryst Pharmaceuticals reported revenue of $874.84M for the fiscal year ended Dec 31, 2025.
How fast is BioCryst Pharmaceuticals' revenue growing?
Revenue was up 94.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 47.8%.
Is BioCryst Pharmaceuticals profitable?
Yes. BioCryst Pharmaceuticals reported net income of $263.86M for the fiscal year ended Dec 31, 2025, with a net margin of 30.2%.
How much free cash flow does BCRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $347.37M minus capital expenditures of $2.47M produced free cash flow of $344.90M.
How much debt does BioCryst Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.63M and cash and equivalents of $89.74M.
BCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts